NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Provista Diagnostics has raised $3.9 million, it said in a regulatory document filed on Monday.
The Scottsdale, Ariz.-based firm did not respond to requests for comment. In a document filed with the US Securities and Exchange Commission, Provista said that there were 24 investors in the private offering of equity. It did not say how the funds would be used.
Provista develops blood-based tests for the diagnosis, prognosis, and monitoring of breast and gynecological cancer patients. In April 2014, it said that it completed a Series B financing round that raised $6 million to fund two prospective clinical trials to evaluate Provista's dtectDx-Breast test. The test is aimed at aiding physicians in determining whether or not to pass patients with suspicious lesions on for a biopsy.
Recently, the company presented data from its studies at the 2015 Miami Breast Cancer Conference suggesting that its combinatorial biomarker panel "is useful in informing the decision to biopsy or continue with six-month follow up," Provista CEO David Reese said in a statement.